Dr. Ronald Hann of the Defense Threat Reduction Agency (DTRA) presents the keynote address on Preparing for the Unthinkable.
Tyler Merkeley of the Biomedical Advanced Research and Development Authority (BARDA) CARB-X program talks about the novel non-dilutive partnership created to promote innovation and foster a robust antimicrobials pipeline.
Paul McQuade of Greenberg Traurig, LLP shares some legal aspects of federal technology investment and their potential impact on intended markets.
Dr. Todd Haim of the National Cancer Institute SBIR Development Center describes the NCI’s SBIR and STTR programs, their structure, the Institute’s funding interests, and FAQs.
Dr. Meg Mooney of the National Cancer Institute discusses new initiatives to accelerate development of cancer therapies in the era of precision medicine.
Mr. Henry Ahn of the National Science Foundation speaks on the NSF’s SBIR and STTR programs.
The largest-ever gathering in the Australian life sciences!
International BioFest 2016 will be the largest-ever gathering in Australian life sciences, with three major conferences coming together in one week in one place as one integrated network. The event will be held from 24-27 October 2016 in Melbourne by AusBiotech.
Conferences include the 17th International Biotechnology Symposium (IBS 2016), presenting the most advanced topics in biotechnology, green chemistry and its related fields; AusBiotech 2016, Australia’s national life science conference; and Australia Biotech Invest, Australia’s life science investment showcase.
Delegates from the biotechnology, biopharmaceutical, life sciences, business, investment, research, academic and health sectors will gather to celebrate Australian and international life sciences and highlight Melbourne as one of the world’s great biotechnology hubs.
FreeMind Group to discuss alternative funding
Ayal Ronen, Vice President, FreeMind Group, will be part of the panel discussing alternative funding, discussing how this flexible funding model can be used within the life science sector. Mr Ronen will be joined by Bill Best, Managing Director, On Market Book Builds, and Ross Curtin, CEO, WealthSpring International Group.
The FreeMind Group is proud to support the upcoming Trans-Pacific Health Science Dialogue!
Where: Boston, MA
When: September 28-29, 2016
Big Players Are Making Big Bets on Biopharma in Asia
- Chinese investors representing more than $5.5B are looking for Trans-Pacific investments
- Pfizer is investing $150M in a biologics plant in China
- BMS expects Opdivo sales in Japan to exceed $1B
- The Hangzhou Economic Development Area is investing $350M in a global biotech center
Can You Afford to Sit on the Sidelines?
The time to think about establishing, expanding or accelerating an Asian strategy is now. With a lineup of top Asia experts, the Trans-Pacific Health Sciences Dialogue will provide you with a solid grasp of Asian biopharma opportunities and today’s best strategies for market entry and growth. This two-day event provides critical insights you will not find at any other meeting.
EARLY REGISRATION ENDS SOON >>> SAVE $300!
For complete details and to register go to:
Website Links
Address
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109